SZSiyi Zhou

Siyi Zhou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Siyi Zhou has a total of 44 co-authors. Here are the top co-authors by number of shared publications:

  • Hailong Yang

    Gannan Medical University

    2 shared publications
  • Hongliang Li

    State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Gannan Innovation and Translational Medicine Research Institute; School of Pharmacy; First Affiliated Hospital, Gannan Medical University, Ganzhou, China

    2 shared publications
  • Hui Liu

    Gannan Medical University

    2 shared publications
  • Jiayi Liu

    Department of Cardiovascular Surgery, Zhongnan Hospital, Wuhan University, Hubei Provincial Engineering Research Center of Minimally Invasive Cardiovascular Surgery, Wuhan Clinical Research Center for Minimally Invasive Treatment of Structural Heart Disease, China (J.L.).

    2 shared publications
  • Jingjing Cai

    State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Gannan Innovation and Translational Medicine Research Institute, School of Pharmacy, First Affiliated Hospital, Gannan Medical University, Ganzhou, China (Yufeng Hu, M.H., S.T., X.C., Y.Z., J.Z., Y.C., X.L., H.Y., L.B., H. Liu, J.W., J.C., X.-J.Z., Z.-G.S., X.Z., H. Li)

    2 shared publications
  • Lan Bai

    State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Gannan Innovation and Translational Medicine Research Institute, School of Pharmacy, First Affiliated Hospital, Gannan Medical University, Ganzhou, China (Yufeng Hu, M.H., S.T., X.C., Y.Z., J.Z., Y.C., X.L., H.Y., L.B., H. Liu, J.W., J.C., X.-J.Z., Z.-G.S., X.Z., H. Li)

    2 shared publications

Latest Publications

  • Novel mTORC1 Booster LAPTM4A Potentiates Pathological Cardiac Hypertrophy

    by Yufeng Hu, Wei Li, Manli Hu, Song Tian, Siyi Zhou, Jiayi Liu, Xu Cheng, Changjiang Zhang, Yingjie Zuo, Jiaxing Zhang, et al.

    BACKGROUND: Excessive unnecessary protein accumulation in cardiomyocyte is a leading contributor for pathological cardiac hypertrophy and has been found closely regulated by the mTORC1 (mechanistic target of rapamycin complex 1) signaling and lysosome transmembrane proteins. However, the precise regulatory mechanism stratifying mTORC1 signaling and the specific functions of lysosomal proteins in protein homeostasis of cardiomyocytes remain largely unidentified. METHODS: We screened lysosomal genes conserved in mice, rats, and humans. Adenoviral infection of rat cardiomyocytes was used to assess the functional role of LAPTM4A (lysosome-associated protein transmembrane 4A). To evaluate its effects in vivo, adeno-associated virus 9 driven by the cardiac troponin T promoter was used for cardiomyocyte-specific expression. RNA sequencing and mass spectrometry–based proteomics were performed to elucidate the underlying molecular mechanisms. Last, a dual-luciferase reporter assay was used to screen a Food and Drug Administration–approved drug library for compounds that suppress LAPTM4A expression. RESULTS: Lysosomal transmembrane proteins expressed in cardiomyocytes were screened for their roles in regulating hypertrophy, and LAPTM4A emerged as a potent promoter of cardiomyocyte hypertrophy and prohypertrophic gene expression. Overexpression of LAPTM4A aggravated cardiac remodeling and dysfunction by enhancing mTORC1-p70S6K (70-kDa ribosomal protein S6 kinase)/4EBP1 (eukaryotic translation initiation factor 4E-binding protein 1)–mediated protein synthesis, without affecting lysosomal autophagy, in a NEDD4L (neural precursor cell expressed developmentally downregulated 4–like)–dependent manner. Mechanistically, LAPTM4A directly interacted with NEDD4L, facilitating K63-linked ubiquitination of AKT (protein kinase B [v-akt murine thymoma viral oncogene homolog]) and subsequent activation of mTORC1 signaling. Cardiomyocyte-specific deletion of LAPTM4A significantly attenuated myocardial hypertrophy and fibrosis induced by transverse aortic constriction in mice. Furthermore, a dual-luciferase reporter screen identified magnolol, a Food and Drug Administration–approved compound, as a suppressor of LAPTM4A expression with marked cardioprotective effects in vivo. CONCLUSIONS: Our study identified a novel mTORC1 booster LAPTM4A and verified interrupting the LAPTM4A-mTORC1 axis can significantly inhibit excessive protein synthesis and pathological cardiac hypertrophy, which might represent an attractive therapeutic approach for this disease.


  • Facilitation of Autophagosome-Lysosome Fusion by LAPTM4A: A Novel Strategy for Attenuating Myocardial Ischemia-Reperfusion Injury

    by Siyi Zhou, Jiayi Liu, Manli Hu, Song Tian, Junjie Zhou, Wei Li, Hailian Chen, Maoji Yin, Shiyi Wang, Lei Luo, et al.

    BACKGROUND: Myocardial ischemia-reperfusion (MIR) injury compromises therapeutic effects of revascularization and leads to functional impairment and exacerbation of structural damage in the heart. Limiting the damage caused by MIR is crucial but is still an unmet clinical need because of the complexity of the underlying mechanisms. Increasing evidence suggests that lysosomal autophagy plays a significant regulatory role in MIR injury. The specific mechanisms involved remain to be fully understood. METHODS: We here systematically analyzed the murine MIR model database to screen the potentially protective lysosome-localized proteins against MIR injury. The positive hits were further functionally screened and validated for their capability on autophagy and hypoxia/reoxygenation insults of cardiomyocytes. After exploring the detailed molecular mechanism underlying the protective effects of the target protein, we generated target gene cardiac-specific knockout mice and overexpression mice to verify its function in mouse MIR injury models. RESULTS: LAPTM4A (lysosome-associated protein transmembrane 4 alpha) stood out as a significant protective lysosome-localized protein from the screening. LAPTM4A deficiency significantly heightened the inflammatory response and cell death both in primary cardiomyocytes and in a MIR-induced mouse model. Conversely, LAPTM4A overexpression exerted protective effects on cell viability and myocardial damage. Mechanistically, LAPTM4A interacts with Rubicon (Run domain Beclin1-interacting and cysteine-rich domain–containing protein), hindering its engagement within the Beclin1 complex, resulting in a robust augmentation of autophagic flux and thereby mitigating cardiac damage during reperfusion. It is important to note that Rubicon knockdown markedly reversed the aggravated injury induced by LAPTM4A knockdown, further verifying the effects of LAPTM4A depend on Rubicon. CONCLUSIONS: Our findings screened out and validated that LAPTM4A is a lysosome-localized protein exerting protective effects against MIR injury by facilitating autophagic flux. Targeting LAPTM4A represents a promising therapeutic strategy for mitigating MIR injury.

  • Fabrication of whole soybean curd using three soymilk preparation techniques

    by Qing Zhang, Siyi Zhou, Jie Chen, Wen Qin, Jiang Liu, Wenyu Yang, Lihua Zhang